{"protocolSection": {"identificationModule": {"nctId": "NCT00614055", "orgStudyIdInfo": {"id": "NN5401-1791"}, "secondaryIdInfos": [{"id": "2007-002476-33", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novo Nordisk A/S", "class": "INDUSTRY"}, "briefTitle": "Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes", "officialTitle": "A 16 Week Randomised, Open Labelled, 3 Armed, Parallel Group, Treat-to-target Trial Comparing Once Daily Injection of SIAC 30 (B), SIAC 45 (B) and Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes Failing on OAD Treatment"}, "statusModule": {"statusVerifiedDate": "2017-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-01"}, "primaryCompletionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-01-30", "studyFirstSubmitQcDate": "2008-01-30", "studyFirstPostDateStruct": {"date": "2008-02-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-10-16", "resultsFirstSubmitQcDate": "2015-10-16", "resultsFirstPostDateStruct": {"date": "2015-11-17", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2009-11-09", "dispFirstSubmitQcDate": "2009-11-09", "dispFirstPostDateStruct": {"date": "2009-11-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-02-09", "lastUpdatePostDateStruct": {"date": "2017-03-20", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novo Nordisk A/S", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (SIAC, insulin degludec/insulin aspart) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive subjects with type 2 diabetes."}, "conditionsModule": {"conditions": ["Diabetes", "Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 178, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Insulin glargine", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: insulin glargine", "Drug: metformin"]}, {"label": "SIAC 30 (B)", "type": "EXPERIMENTAL", "interventionNames": ["Drug: insulin degludec/insulin aspart", "Drug: metformin"]}, {"label": "SIAC 45 (B)", "type": "EXPERIMENTAL", "interventionNames": ["Drug: insulin degludec/insulin aspart", "Drug: metformin"]}], "interventions": [{"type": "DRUG", "name": "insulin degludec/insulin aspart", "description": "Formulation 1: Treat-to-target dose titration scheme, injection s.c., once daily", "armGroupLabels": ["SIAC 30 (B)"]}, {"type": "DRUG", "name": "insulin degludec/insulin aspart", "description": "Formulation 2: Treat-to-target dose titration scheme, injection s.c., once daily", "armGroupLabels": ["SIAC 45 (B)"]}, {"type": "DRUG", "name": "insulin glargine", "description": "Treat-to-target dose titration scheme, injection s.c., once daily", "armGroupLabels": ["Insulin glargine"]}, {"type": "DRUG", "name": "metformin", "description": "Tablets, 1500-2000 mg/day", "armGroupLabels": ["Insulin glargine", "SIAC 30 (B)", "SIAC 45 (B)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Glycosylated Haemoglobin (HbA1c)", "description": "Change from baseline in HbA1c after 16 weeks of treatment", "timeFrame": "Week 0, Week 16"}], "secondaryOutcomes": [{"measure": "Change in Fasting Plasma Glucose (FPG)", "description": "Change from baseline in FPG after 16 weeks of treatment", "timeFrame": "Week 0, Week 16"}, {"measure": "Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)", "description": "Mean of SMPG after 16 weeks of treatment. Plasma glucose measured: before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, bedtime, at 4 am and before breakfast.", "timeFrame": "Week 16"}, {"measure": "Rate of Treatment Emergent Adverse Events (AEs)", "description": "Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.", "timeFrame": "Week 0 to Week 16 + 5 days follow up"}, {"measure": "Rate of Major and Minor Hypoglycaemic Episodes", "description": "Rate of Major and Minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L.", "timeFrame": "Week 0 to Week 16 + 5 days follow up"}, {"measure": "Rate of Nocturnal Major and Minor Hypoglycaemic Episodes", "description": "Rate of nocturnal Major and Minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Episodes were defined as nocturnal if the time of onset was between 23:00 (included) and 06:00 (excluded).", "timeFrame": "Week 0 to Week 16 + 5 days follow up"}, {"measure": "Laboratory Safety Parameters (Biochemistry): Alanine Aminotransferase (ALAT)", "description": "Values at screening (Week -4) and at Week 16", "timeFrame": "Week -4, Week 16"}, {"measure": "Laboratory Safety Parameters (Biochemistry): Aspartate Aminotransferase (ASAT)", "description": "Values at screening (Week -4) and at Week 16", "timeFrame": "Week -4, Week 16"}, {"measure": "Laboratory Safety Parameters (Biochemistry): Serum Creatinine", "description": "Values at screening (Week -4) and at Week 16", "timeFrame": "Week -4, Week 16"}, {"measure": "Vital Signs: Diastolic Blood Pressure (BP)", "description": "Values at baseline (Week 0) and at Week 16", "timeFrame": "Week 0, Week 16"}, {"measure": "Vital Signs: Systolic Blood Pressure (BP)", "description": "Values at baseline (Week 0) and at Week 16", "timeFrame": "Week 0, Week 16"}, {"measure": "Vital Signs: Pulse", "description": "Values at baseline (Week 0) and at Week 16", "timeFrame": "Week 0, Week 16"}, {"measure": "Physical Examination", "description": "Physical examination is performed at baseline (Week 0) and after 8 and 16 weeks of treatment. If any new findings or deterioration in previous findings were observed during the trial, these were recorded as AEs and are therefore not presented separately as no analysis was performed.", "timeFrame": "Week 0, Week 8, Week 16"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.)\n* Insulin na\u00efve type 2 diabetes subjects (as diagnosed clinically) for at least 3 months (no previous insulin treatment or previous short term insulin treatment maximum 14 days within the last 3 months)\n* Treatment with one or two oral anti-diabetic drugs (OADs): metformin, sulfonylurea, other insulin secretagogue (e.g. repaglinide, nateglinide), alpha-glucosidase inhibitors for at least 2 month at a stable maximum tolerated dose or at least half maximum allowed dose according to locally approved summary of product characteristics (SPC)\n* HbA1c, 7.0 - 11.0 % (both inclusive)\n* Body Mass Index (BMI), 25.0 - 37.0 kg/m\\^2 (both inclusive)\n\nExclusion Criteria:\n\n* Metformin contraindication according to local practice\n* Thiazolidinedione (TZD) treatments within the previous three months prior to Visit 1\n* Any systemic treatment with products, which in the investigator's opinion could interfere with glucose or lipid metabolism (e.g. systemic corticosteroids) within 3 months prior to randomisation\n* Subject has a clinically significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, neurological, genitourinary, or haematological system that, in the opinion of the investigator, may confound the results of the trial or pose additional risk in administering trial product", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Global Clinical Registry (GCR, 1452)", "affiliation": "Novo Nordisk A/S", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novo Nordisk Investigational Site", "city": "Al\u00e8s", "zip": "30100", "country": "France", "geoPoint": {"lat": 44.12489, "lon": 4.08082}}, {"facility": "Novo Nordisk Investigational Site", "city": "Brest", "zip": "29609", "country": "France", "geoPoint": {"lat": 48.3903, "lon": -4.48628}}, {"facility": "Novo Nordisk Investigational Site", "city": "LA ROCHELLE cedex", "zip": "17019", "country": "France", "geoPoint": {"lat": 46.16667, "lon": -1.15}}, {"facility": "Novo Nordisk Investigational Site", "city": "Le Creusot", "zip": "71200", "country": "France", "geoPoint": {"lat": 46.80714, "lon": 4.41632}}, {"facility": "Novo Nordisk Investigational Site", "city": "Mont de Marsan", "zip": "40024", "country": "France", "geoPoint": {"lat": 43.89022, "lon": -0.49713}}, {"facility": "Novo Nordisk Investigational Site", "city": "Venissieux", "zip": "69200", "country": "France", "geoPoint": {"lat": 45.70254, "lon": 4.87147}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bad Kreuznach", "zip": "55545", "country": "Germany", "geoPoint": {"lat": 49.8414, "lon": 7.86713}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bad Mergentheim", "zip": "97980", "country": "Germany", "geoPoint": {"lat": 49.4925, "lon": 9.77361}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dormagen", "zip": "41539", "country": "Germany", "geoPoint": {"lat": 51.09683, "lon": 6.83167}}, {"facility": "Novo Nordisk Investigational Site", "city": "Hohenm\u00f6lsen", "zip": "06679", "country": "Germany", "geoPoint": {"lat": 51.15769, "lon": 12.1}}, {"facility": "Novo Nordisk Investigational Site", "city": "Neuss", "zip": "41460", "country": "Germany", "geoPoint": {"lat": 51.19807, "lon": 6.68504}}, {"facility": "Novo Nordisk Investigational Site", "city": "Neuwied", "zip": "56564", "country": "Germany", "geoPoint": {"lat": 50.4336, "lon": 7.47057}}, {"facility": "Novo Nordisk Investigational Site", "city": "Elverum", "zip": "2408", "country": "Norway", "geoPoint": {"lat": 60.88191, "lon": 11.56231}}, {"facility": "Novo Nordisk Investigational Site", "city": "Hamar", "zip": "2317", "country": "Norway", "geoPoint": {"lat": 60.7945, "lon": 11.06798}}, {"facility": "Novo Nordisk Investigational Site", "city": "Kongsvinger", "zip": "2212", "country": "Norway", "geoPoint": {"lat": 60.19049, "lon": 11.99772}}, {"facility": "Novo Nordisk Investigational Site", "city": "Oslo", "zip": "0586", "country": "Norway", "geoPoint": {"lat": 59.91273, "lon": 10.74609}}, {"facility": "Novo Nordisk Investigational Site", "city": "Stavanger", "zip": "4011", "country": "Norway", "geoPoint": {"lat": 58.97005, "lon": 5.73332}}, {"facility": "Novo Nordisk Investigational Site", "city": "Troms\u00f8", "zip": "9038", "country": "Norway", "geoPoint": {"lat": 69.6489, "lon": 18.95508}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bucharest", "zip": "011234", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bucharest", "zip": "020042", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bucharest", "zip": "020475", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bucharest", "zip": "020992", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Novo Nordisk Investigational Site", "city": "Almer\u00eda", "zip": "04001", "country": "Spain", "geoPoint": {"lat": 36.83814, "lon": -2.45974}}, {"facility": "Novo Nordisk Investigational Site", "city": "Partida de Bacarot", "zip": "03114", "country": "Spain"}, {"facility": "Novo Nordisk Investigational Site", "city": "Sevilla", "zip": "41010", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "Novo Nordisk Investigational Site", "city": "Valencia", "zip": "46014", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"facility": "Novo Nordisk Investigational Site", "city": "Valladolid", "zip": "47011", "country": "Spain", "geoPoint": {"lat": 41.65518, "lon": -4.72372}}]}, "referencesModule": {"references": [{"pmid": "21285389", "type": "RESULT", "citation": "Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A, Romero E, Mersebach H, Dykiel P, Jorde R. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011 Mar;34(3):669-74. doi: 10.2337/dc10-1905. Epub 2011 Feb 1."}, {"pmid": "22946603", "type": "RESULT", "citation": "Ma Z, Parkner T, Christiansen JS, Laursen T. IDegAsp: a novel soluble insulin analogs combination. Expert Opin Biol Ther. 2012 Nov;12(11):1533-40. doi: 10.1517/14712598.2012.722203. Epub 2012 Sep 4."}, {"pmid": "24124961", "type": "RESULT", "citation": "Liebl A, Davidson J, Mersebach H, Dykiel P, Tack CJ, Heise T. A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial. J Diabetes Sci Technol. 2013 Sep 1;7(5):1328-36. doi: 10.1177/193229681300700524."}], "seeAlsoLinks": [{"label": "Clinical Trials at Novo Nordisk", "url": "http://novonordisk-trials.com"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "During a run-in period of 2 weeks, metformin was up-titrated to 1500/ 2000 mg/day, which was maintained for 1 week. Subjects who tolerated the metformin dose for a week and had a median of 3 self measured glucose values before breakfast, on 3 consecutive days before randomisation, of \u2265 7.5 mmol/l, were randomised to 1 of the 3 treatment groups", "recruitmentDetails": "The trial was conducted at 22 sites in 5 countries: France (4 sites), Germany (5 sites), Norway (5 sites), Romania (3 sites) and Spain (5 sites).", "groups": [{"id": "FG000", "title": "SIAC 30 (B)", "description": "Soluble insulin analogue combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "FG001", "title": "SIAC 45 (B)", "description": "Soluble insulin analogue combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "FG002", "title": "Insulin Glargine", "description": "Insulin glargine was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "59"}, {"groupId": "FG001", "numSubjects": "59"}, {"groupId": "FG002", "numSubjects": "60"}]}, {"type": "Exposed", "achievements": [{"groupId": "FG000", "numSubjects": "59"}, {"groupId": "FG001", "numSubjects": "59"}, {"groupId": "FG002", "numSubjects": "60"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "55"}, {"groupId": "FG001", "numSubjects": "53"}, {"groupId": "FG002", "numSubjects": "55"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Unclassified", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "SIAC 30 (B)", "description": "Soluble insulin analogue combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "BG001", "title": "SIAC 45 (B)", "description": "Soluble insulin analogue combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "BG002", "title": "Insulin Glargine", "description": "Insulin glargine was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "59"}, {"groupId": "BG001", "value": "59"}, {"groupId": "BG002", "value": "60"}, {"groupId": "BG003", "value": "178"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.7", "spread": "8.8"}, {"groupId": "BG001", "value": "60.2", "spread": "8.4"}, {"groupId": "BG002", "value": "58.4", "spread": "8.4"}, {"groupId": "BG003", "value": "59.1", "spread": "8.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "16"}, {"groupId": "BG003", "value": "63"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "44"}, {"groupId": "BG003", "value": "115"}]}]}]}, {"title": "Glycosylated haemoglobin (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of glycosylated haemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.3", "spread": "1.2"}, {"groupId": "BG001", "value": "8.6", "spread": "1.5"}, {"groupId": "BG002", "value": "8.4", "spread": "1.3"}, {"groupId": "BG003", "value": "8.5", "spread": "1.3"}]}]}]}, {"title": "Fasting plasma glucose (FPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "11.1", "spread": "3.3"}, {"groupId": "BG001", "value": "11.5", "spread": "3.2"}, {"groupId": "BG002", "value": "12.1", "spread": "3.5"}, {"groupId": "BG003", "value": "11.6", "spread": "3.3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Glycosylated Haemoglobin (HbA1c)", "description": "Change from baseline in HbA1c after 16 weeks of treatment", "populationDescription": "Full analysis set (FAS) included all randomised subjects and missing data was imputed using last observation carried forward (LOCF).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of glycosylated haemoglobin", "timeFrame": "Week 0, Week 16", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble insulin analogue combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble insulin analogue combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "Insulin Glargine", "description": "Insulin glargine was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.31", "spread": "1.01"}, {"groupId": "OG001", "value": "-1.46", "spread": "1.39"}, {"groupId": "OG002", "value": "-1.29", "spread": "1.10"}]}]}]}, {"type": "SECONDARY", "title": "Change in Fasting Plasma Glucose (FPG)", "description": "Change from baseline in FPG after 16 weeks of treatment", "populationDescription": "The FAS included all randomised subjects and missing data was imputed using LOCF.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, Week 16", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble insulin analogue combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble insulin analogue combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "Insulin Glargine", "description": "Insulin glargine was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.30", "spread": "3.45"}, {"groupId": "OG001", "value": "-4.10", "spread": "3.09"}, {"groupId": "OG002", "value": "-5.07", "spread": "3.85"}]}]}]}, {"type": "SECONDARY", "title": "Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)", "description": "Mean of SMPG after 16 weeks of treatment. Plasma glucose measured: before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, bedtime, at 4 am and before breakfast.", "populationDescription": "The FAS included all randomised subjects and missing data was imputed using LOCF.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 16", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble insulin analogue combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble insulin analogue combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "Insulin Glargine", "description": "Insulin glargine was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.34", "spread": "0.75"}, {"groupId": "OG001", "value": "8.31", "spread": "0.78"}, {"groupId": "OG002", "value": "8.42", "spread": "0.78"}]}]}]}, {"type": "SECONDARY", "title": "Rate of Treatment Emergent Adverse Events (AEs)", "description": "Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.", "populationDescription": "Safety analysis set (SAS) included all subjects who received at least one dose of the investigational product or its comparator.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Events/100 years of patient exposure", "timeFrame": "Week 0 to Week 16 + 5 days follow up", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble insulin analogue combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble insulin analogue combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "Insulin Glargine", "description": "Insulin glargine was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}]}], "classes": [{"title": "Adverse events (AEs)", "categories": [{"measurements": [{"groupId": "OG000", "value": "441"}, {"groupId": "OG001", "value": "310"}, {"groupId": "OG002", "value": "295"}]}]}, {"title": "Serious AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Severe AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Moderate AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "138"}, {"groupId": "OG001", "value": "123"}, {"groupId": "OG002", "value": "61"}]}]}, {"title": "Mild AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "298"}, {"groupId": "OG001", "value": "187"}, {"groupId": "OG002", "value": "234"}]}]}, {"title": "Fatal AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Rate of Major and Minor Hypoglycaemic Episodes", "description": "Rate of Major and Minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L.", "populationDescription": "The FAS included all randomised subjects.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Episodes/100 years of patient exposure", "timeFrame": "Week 0 to Week 16 + 5 days follow up", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble insulin analogue combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble insulin analogue combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "Insulin Glargine", "description": "Insulin glargine was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}]}], "classes": [{"title": "Major", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Minor", "categories": [{"measurements": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "240"}, {"groupId": "OG002", "value": "67"}]}]}]}, {"type": "SECONDARY", "title": "Rate of Nocturnal Major and Minor Hypoglycaemic Episodes", "description": "Rate of nocturnal Major and Minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Episodes were defined as nocturnal if the time of onset was between 23:00 (included) and 06:00 (excluded).", "populationDescription": "The FAS included all randomised subjects.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Episodes/100 years of patient exposure", "timeFrame": "Week 0 to Week 16 + 5 days follow up", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble insulin analogue combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble insulin analogue combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "Insulin Glargine", "description": "Insulin glargine was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}]}], "classes": [{"title": "Major", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Minor", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "158"}, {"groupId": "OG002", "value": "17"}]}]}]}, {"type": "SECONDARY", "title": "Laboratory Safety Parameters (Biochemistry): Alanine Aminotransferase (ALAT)", "description": "Values at screening (Week -4) and at Week 16", "populationDescription": "The SAS included all subjects who received at least one dose of the investigational product or its comparator.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "IU/L", "timeFrame": "Week -4, Week 16", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble insulin analogue combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble insulin analogue combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "Insulin Glargine", "description": "Insulin glargine was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}]}], "classes": [{"title": "Week -4 , N=58, 59, 60", "categories": [{"measurements": [{"groupId": "OG000", "value": "31.9", "spread": "18.3"}, {"groupId": "OG001", "value": "29.7", "spread": "15.3"}, {"groupId": "OG002", "value": "33.7", "spread": "23.1"}]}]}, {"title": "Week 16 , N=54, 54, 57", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.9", "spread": "13.1"}, {"groupId": "OG001", "value": "23.2", "spread": "9.7"}, {"groupId": "OG002", "value": "22.3", "spread": "10.3"}]}]}]}, {"type": "SECONDARY", "title": "Laboratory Safety Parameters (Biochemistry): Aspartate Aminotransferase (ASAT)", "description": "Values at screening (Week -4) and at Week 16", "populationDescription": "The SAS included all subjects who received at least one dose of the investigational product or its comparator.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "IU/L", "timeFrame": "Week -4, Week 16", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble insulin analogue combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble insulin analogue combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "Insulin Glargine", "description": "Insulin glargine was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}]}], "classes": [{"title": "Week -4, N=58, 59, 60", "categories": [{"measurements": [{"groupId": "OG000", "value": "24.8", "spread": "14.6"}, {"groupId": "OG001", "value": "22.0", "spread": "8.3"}, {"groupId": "OG002", "value": "24.0", "spread": "14.1"}]}]}, {"title": "Week 16, N=54, 54, 57", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.1", "spread": "8.2"}, {"groupId": "OG001", "value": "20.0", "spread": "5.8"}, {"groupId": "OG002", "value": "19.2", "spread": "6.4"}]}]}]}, {"type": "SECONDARY", "title": "Laboratory Safety Parameters (Biochemistry): Serum Creatinine", "description": "Values at screening (Week -4) and at Week 16", "populationDescription": "The SAS included all subjects who received at least one dose of the investigational product or its comparator.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "umol/L", "timeFrame": "Week -4, Week 16", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble insulin analogue combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble insulin analogue combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "Insulin Glargine", "description": "Insulin glargine was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}]}], "classes": [{"title": "Week -4 , N=58, 59, 60", "categories": [{"measurements": [{"groupId": "OG000", "value": "76.4", "spread": "15.4"}, {"groupId": "OG001", "value": "75.8", "spread": "14.4"}, {"groupId": "OG002", "value": "77.4", "spread": "13.9"}]}]}, {"title": "Week 16 , N=54, 54, 57", "categories": [{"measurements": [{"groupId": "OG000", "value": "75.7", "spread": "15.4"}, {"groupId": "OG001", "value": "74.9", "spread": "15.6"}, {"groupId": "OG002", "value": "76.8", "spread": "14.6"}]}]}]}, {"type": "SECONDARY", "title": "Vital Signs: Diastolic Blood Pressure (BP)", "description": "Values at baseline (Week 0) and at Week 16", "populationDescription": "The SAS included all subjects who received at least one dose of the investigational product or its comparator.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Week 0, Week 16", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble insulin analogue combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble insulin analogue combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "Insulin Glargine", "description": "Insulin glargine was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}]}], "classes": [{"title": "Week 0 (Baseline), N=59, 59, 60", "categories": [{"measurements": [{"groupId": "OG000", "value": "78", "spread": "8"}, {"groupId": "OG001", "value": "78", "spread": "8"}, {"groupId": "OG002", "value": "79", "spread": "8"}]}]}, {"title": "Week 16, N=56, 53, 58", "categories": [{"measurements": [{"groupId": "OG000", "value": "76", "spread": "8"}, {"groupId": "OG001", "value": "77", "spread": "9"}, {"groupId": "OG002", "value": "77", "spread": "7"}]}]}]}, {"type": "SECONDARY", "title": "Vital Signs: Systolic Blood Pressure (BP)", "description": "Values at baseline (Week 0) and at Week 16", "populationDescription": "The SAS included all subjects who received at least one dose of the investigational product or its comparator.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Week 0, Week 16", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble insulin analogue combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble insulin analogue combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "Insulin Glargine", "description": "Insulin glargine was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}]}], "classes": [{"title": "Week 0 (Baseline), N=59, 59, 60", "categories": [{"measurements": [{"groupId": "OG000", "value": "135", "spread": "15"}, {"groupId": "OG001", "value": "133", "spread": "14"}, {"groupId": "OG002", "value": "135", "spread": "15"}]}]}, {"title": "Week 16, N=56, 53, 58", "categories": [{"measurements": [{"groupId": "OG000", "value": "129", "spread": "13"}, {"groupId": "OG001", "value": "133", "spread": "12"}, {"groupId": "OG002", "value": "129", "spread": "12"}]}]}]}, {"type": "SECONDARY", "title": "Vital Signs: Pulse", "description": "Values at baseline (Week 0) and at Week 16", "populationDescription": "The SAS included all subjects who received at least one dose of the investigational product or its comparator.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats/minute", "timeFrame": "Week 0, Week 16", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble insulin analogue combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble insulin analogue combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "Insulin Glargine", "description": "Insulin glargine was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "60"}]}], "classes": [{"title": "Week 0 (Baseline), N=59, 59, 60", "categories": [{"measurements": [{"groupId": "OG000", "value": "73", "spread": "10"}, {"groupId": "OG001", "value": "75", "spread": "10"}, {"groupId": "OG002", "value": "75", "spread": "9"}]}]}, {"title": "Week 16, N=56, 53, 58", "categories": [{"measurements": [{"groupId": "OG000", "value": "71", "spread": "10"}, {"groupId": "OG001", "value": "69", "spread": "9"}, {"groupId": "OG002", "value": "71", "spread": "11"}]}]}]}, {"type": "SECONDARY", "title": "Physical Examination", "description": "Physical examination is performed at baseline (Week 0) and after 8 and 16 weeks of treatment. If any new findings or deterioration in previous findings were observed during the trial, these were recorded as AEs and are therefore not presented separately as no analysis was performed.", "reportingStatus": "POSTED", "timeFrame": "Week 0, Week 8, Week 16", "groups": [{"id": "OG000", "title": "Insulin Glargine", "description": "Insulin glargine was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 30 (B)", "description": "Soluble insulin analogue combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "SIAC 45 (B)", "description": "Soluble insulin analogue combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "The adverse events were collected in a time frame of 16 weeks + 7 days follow up", "description": "The SAS included all subjects who received at least one dose of the investigational product or its comparator.", "eventGroups": [{"id": "EG000", "title": "SIAC 30 (B)", "description": "Soluble insulin analogue combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted.", "seriousNumAffected": 2, "seriousNumAtRisk": 59, "otherNumAffected": 23, "otherNumAtRisk": 59}, {"id": "EG001", "title": "SIAC 45 (B)", "description": "Soluble insulin analogue combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml; formulation B) was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted.", "seriousNumAffected": 1, "seriousNumAtRisk": 59, "otherNumAffected": 16, "otherNumAtRisk": 59}, {"id": "EG002", "title": "Insulin Glargine", "description": "Insulin glargine was given subcutaneously once daily (OD) before dinner in combination with at least 1500 mg/day metformin (tablets) for 16 weeks. Insulin doses were individually adjusted.", "seriousNumAffected": 0, "seriousNumAtRisk": 60, "otherNumAffected": 13, "otherNumAtRisk": 60}], "seriousEvents": [{"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}]}], "otherEvents": [{"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 59}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 60}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 60}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 59}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 3, "numAffected": 1, "numAtRisk": 60}]}, {"term": "C-reactive protein increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 14, "numAtRisk": 59}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 9, "numAffected": 9, "numAtRisk": 60}]}, {"term": "Dyslipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 59}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 6, "numAffected": 6, "numAtRisk": 60}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication."}, "pointOfContact": {"title": "Public Access to Clinical Trials", "organization": "Novo Nordisk A/S", "email": "clinicaltrials@novonordisk.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000007328", "term": "Insulin"}, {"id": "C000557859", "term": "Insulin, Globin Zinc"}, {"id": "D000008687", "term": "Metformin"}, {"id": "D000069036", "term": "Insulin Glargine"}, {"id": "D000061267", "term": "Insulin Aspart"}, {"id": "D000049528", "term": "Insulin, Long-Acting"}, {"id": "C000578220", "term": "Insulin degludec, insulin aspart drug combination"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M29801", "name": "Insulin Aspart", "asFound": "Obtained", "relevance": "HIGH"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Interaction", "relevance": "HIGH"}, {"id": "M17768", "name": "Zinc", "relevance": "LOW"}, {"id": "M26073", "name": "Insulin, Long-Acting", "asFound": "Epinephrine", "relevance": "HIGH"}, {"id": "M117006", "name": "Insulin degludec, insulin aspart drug combination", "asFound": "Obtained", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Micro", "name": "Micronutrients"}]}}, "hasResults": true}